App-Quantinova.ai

Production of platelets in vitro in functionalised 3-dimensional scaffolds mimicking the bone marrow niche

H. Foster - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Proof of principle of a fast and fully automated FVIII functional inhibitor test

B. Verbruggen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

FVIII

Rac1 inhibition causes impaired GPVI signalling in human platelets through GPVI shedding and loss of PLCγ2 phosphorylation

R. Neagoe - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Evithrom

Real World Data : Safety and Mortality Monitoring the patients on Rivaroxaban in our center

F. Alayoubi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Non-valvular atrial fibrillation

rivaroxaban

Real-time assessment of inter-platelet communication and coordination of calcium signals by connexin gap junctions

K. Taylor - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Fibrinogen (IV)

Real-world efficacy of extended half-life Factor VIII in patients with haemophilia A on prophylaxis

K. White - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A – results from A-SURE, a 24-month prospective, non-interventional study

J. Oldenburg - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hemophilia

Recombinant Factor VIII

Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

J. Mahlangu - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients with Hemophilia B

G. Young - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Tacrolimus

Results in Patients with Heparin Induced Thrombocytopenia or Vaccine Induced Thrombocytopenia with Thrombosis Confirm the Unsuitability of Using APTT Ratio to Monitor Argatroban Therapy

S. Platton - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Thrombocytopenia

Argatroban

Results of a Single-centre Targeted Screening Approach to Identify Potential Occult Cases of Pregnancy-associated Thrombotic Thrombocytopenic Purpura (TTP).

L. Neave - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

N/A

Retrotransposon insertions: a challenging detection and characterization solved by long-read nanopore sequencing. Relevance in antithrombin deficiency

B. de la Morena-Barrio - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Review of a Peri-operative mobile application to conform anticoagulation management and review of safety and clinician satisfaction.

J. Ruell - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Rivaroxaban for management of Superficial Vein Thrombosis

M. Rees - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Angiology

Superficial Vein Thrombosis

rivaroxaban

Routine Measurement of Direct Factor Xa Inhibiting Anticoagulants

M. Dave - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Heparin

Safety and Efficacy of Apixaban as Thromboprophylaxis in Multiple Myeloma Patients Receiving Chemotherapy: a Prospective Cohort Study

Z. Sayar - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Multiple Myeloma

apixaban

Safety and efficacy of direct oral anticoagulant in elderly patients with cancer: real-world challenges

F. Haque - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Safety and efficacy of simoctocog alfa in patients with haemophilia A in routine clinical practice (GENA-99)

C. Berger - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

simoctocog alfa

Serial Thrombopoietin Levels in Immune Thrombocytopenia Patients on Treatment.

P. Woolley - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Severe Covid-19 Infection in Pregnancy complicated by Heparin Induced Thrombocytopenia

S. Kazi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Thrombocytopenia

Tocilizumab

Filters

45280 Abstracts